- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05195658
Acute Stroke of CArotid Artery Bifurcation Origin Treated With Use oF the MicronEt-covered CGUARD (SAFEGUARD-STROKE)
Acute Stroke of CArotid Artery Bifurcation Origin Treated With Use oF The MicronEt-covered CGUARD STent Under TRansient FlOw Reversal LinKed With Thrombus REtrieval: SAFEGUARD-STROKE Study
Prospective, single-center, clinical registry of patients with acute stroke of carotid artery bifurcation origin undergoing endovascular treatment using the Micronet-covered CGUARD Stent to seal the culprit lesion under proximal cerebral protection (by transient flow reversal using balloon catheter such as the MoMa or FlowGate) with thrombus retrieval achieved through active aspiration ± stentriever use.
A study involving clinical and cerebrovascular imaging data evaluation in consecutive patients with acute stroke of carotid artery bifurcation origin, presenting in the time-window and/or cerebral tissue window allowing guideline-indicated reperfusion by interventional management.
A registry of consecutive patients with the study condition. An open-label study, without randomization - a single arm, single-center study in John Paul II Hospital in Krakow, Poland.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute stroke of carotid artery bifurcation origin presents a major treatment challenge. With the large volume of affected brain tissue, this stroke type -if left untreated- has an extremely unfavorable prognosis. With a typical large thrombus load in the extracranial carotid artery, the efficacy of systemic intravenous thrombolysis - the mainstay of ischemic stroke treatment- is very poor (reported recanalization rates <5%). With a high risk of complications (including cerebral embolism) and poor clinical outcomes, patients with acute stroke of carotid artery bifurcation origin (≈20-30% large-vessel occlusion strokes) are underrepresented in stroke mechanical reperfusion trials that have typically not included such patients.
No contemporary clinical studies have been dedicated specifically to management acute stroke of carotid artery bifurcation origin. In contrast to cerebral artery occlusion, in which the treatment algorithm is well-established, in the stroke of carotid artery bifurcation origin neither the reperfusion window nor the optimal revascularization method are yet determined. This results in a low level of evidence regarding the choice of a particular treatment method - endovascular emergent mechanical revascularization or surgical. Carotid surgery in acute major stroke setting is particularly challenging. Also, the surgical treatment modality is unable to address the problem of acute embolus in the large intracerebral vessel(s) that co-exists in about one in every three patients with acute stroke of carotid bifurcation origin.
With regard to minimally-invasive endovascular treatment, one fundamental limitation of the carotid stents used so far to address the culprit lesion (single-layer, first-generation stents) has been their inability to adequately sequestrate (insulate) the atherothrombotic lesion, resulting in an increased risk of new cerebral embolism and enhancing the risk of stent acute occlusion. Circumstantial evidence suggests that the Micronet-covered stent (in particular in combination with 'proximal' cerebral protection and, whenever indicated and feasible, in combination with aspiration or stentriever thrombectomy) may increase both safety and efficacy of carotid revascularization in acute stroke of carotid bifurcation origin.
A novel dual-layered Micronet-covered stent system (CGuard) has been demonstrated to markedly reduce peri- (and eliminate post-) procedural cerebral embolism in elective carotid artery stenting (Level 1 evidence) but has not yet been systematically tested in the emergent setting. This prospective, single-center, clinical registry of patients with acute stroke of carotid artery bifurcation origin eligible for endovascular interventional management will evaluate the use of Micronet-covered Stent (CGuard) to seal the stroke culprit lesion and reconstruct the lumen of the artery supplying the brain. Proximal cerebral protection (by transient flow reversal using a balloon guide catheter such as the MoMa or FlowGate) is used whenever feasible. In addition, extra/intra-cranial thrombus retrieval will be performed as clinically indicated, using either the aspiration technique and/or a stentriever.
Eligibility for study treatment is based on the decision (recommendation) of a multidisciplinary NeuroVascular Team Committee, consisting of a cardioangiologist certified in stroke mechanical thrombectomy or an interventional (neuro)radiologist, stroke neurologist and anesthesiologist. Use of pharmacologic agents and intended devices is according to international guidelines and instructions for use.
The study involves evaluation of clinical and cerebrovascular imaging data (presentation, outcome) in consecutive patients with acute stroke of carotid artery bifurcation origin, presenting in the time-window and/or cerebral tissue window (salvageable cerebral tissue, small cerebral infarct core/large penumbra) allowing guideline-indicated reperfusion by interventional management. Cerebral and vascular non-invasive imaging will involve computed tomography and/or magnetic resonance imaging modalities as clinically indicated.
The study is a registry of consecutive patients with the study condition, treated using the device of interest. This is an open-label study, without randomization - a single arm, single-center study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Piotr Musialek, MD, DPhil
- Phone Number: +48126142287
- Email: pmusialek@szpitaljp2.krakow.pl
Study Contact Backup
- Name: Lukasz Tekieli, MD, PhD
- Phone Number: +48126143501
- Email: luk.tekieli@gmail.com
Study Locations
-
-
-
Krakow, Poland, 31-202
- Recruiting
- Department of Cardiac and Vascular Diseases, John Paul II Hospital
-
Contact:
- Piotr Musialek, MD, DPhil
- Phone Number: +48126142287
- Email: pmusialek@szpitaljp2.krakow.pl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Consecutive patients with acute ischemic stroke with carotid artery bifurcation stenosis/occlusion as culprit lesion.
- Clinical picture of acute ischemic stroke, stroke-in-evolution, or crescendo TIAs.
- Patient eligible for endovascular stroke therapy according to AHA/ASA stroke management and accepted for emergent stroke intervention by the local NeuroVascular Team Committee according to local standard of practice.
- Signed informed consent form to participate in the study (obtained at the point of first feasibility; note that live-saving procedure track may be executed for performing intervention according to local regulations and routine practice in the center)
- Consent to (routinely performed in this group of patients) follow-up visits that may include imaging as per routine practice in the study center and as clinically indicated.
Exclusion Criteria:
- Known stroke cause other than the carotid bifurcation lesion
- Lack of effective endovascular route needed for intervention
- Any known contraindications to stroke endovascular management
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute ischemic stroke with culprit lesion at the carotid bifurcation
Consecutive patients with acute ischemic stroke culprit lesion at the carotid bifurcation, accepted for emergent interventional management by the NeuroVascular Team Committee according to stroke management guidelines
|
Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection. Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever. Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center. Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from poor clinical status at 90 days
Time Frame: 90 days from index procedure
|
Freedom from poor clinical status (expressed as modified Rankin score, mRS >2) at 90 days
|
90 days from index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from major clinical complications comprising MACNE (major adverse cardiovascular or neurologic event) at 30 days
Time Frame: At 30 days from index procedure
|
Freedom from any death, any new stroke (ischemic or hemorrhagic, including hemorrhagic transformation of index stroke), and myocardial infarction at 30-day follow-up
|
At 30 days from index procedure
|
Freedom from major clinical complications comprising MACNE at 90 days
Time Frame: At 90 days from index procedure
|
Freedom from any death, any new stroke (ischemic or hemorrhagic, including hemorrhagic transformation of index stroke), and myocardial infarction at 90-day follow-up
|
At 90 days from index procedure
|
Freedom from major clinical complications comprising MACNE at 12 months
Time Frame: At 12 months from index procedure
|
Freedom from any death, any new stroke (ischemic or hemorrhagic, including hemorrhagic transformation of index stroke), and myocardial infarction at 12-months follow-up
|
At 12 months from index procedure
|
Procedural success rate for carotid intervention
Time Frame: Periprocedural
|
Rate of patients with success of endovascular treatment of the culprit carotid lesion i.e. procedural success (stent delivery and implantation, withdrawal of stent delivery system, residual stenosis ≤30% of vessel lumen diameter, procedure without complications)
|
Periprocedural
|
Technical success rate for carotid intervention
Time Frame: At procedure completion
|
Number of procedures completed using the study device in relation to the number of attempted procedures
|
At procedure completion
|
Clinical success rate for carotid intervention
Time Frame: 90 days after procedure
|
Number of procedures completed with a good clinical outcome (mRS 0-2 at 90 days) in relation to the number of attempted procedures
|
90 days after procedure
|
Rate of successful cerebral recanalization
Time Frame: At procedure completion
|
Rate of patients with index hemisphere optimal cerebral flow post-procedurally (modified TICI 2b or 3)
|
At procedure completion
|
Freedom from embolism to the new territory during procedure
Time Frame: During index procedure
|
Freedom from embolism to the new territory at the post-procedural angiogram
|
During index procedure
|
Rate of peri-procedural cerebral complications
Time Frame: At procedure completion
|
Rate of patients with peri-procedural cerebral complications such as embolism to new territory or symptomatic intracranial haemorrhage (i.e.
parenchymal haematoma on imaging with clinical deterioration).
|
At procedure completion
|
Rate of other major periprocedural complications
Time Frame: Up to 7 days post-procedure
|
Rate of patients with other major peri-procedural complications: acute renal failure, systemic infection, respiratory failure requiring prolonged ventilation (>24 hours), vascular access site complication requiring surgery
|
Up to 7 days post-procedure
|
New ipsilateral stroke free survival up to 1 year
Time Frame: From procedure completion till 1 year post-procedure
|
Survival without any stroke up to 1 year follow up
|
From procedure completion till 1 year post-procedure
|
New ipsilateral stroke free survival up to 5 year
Time Frame: From procedure completion till 5 years post-procedure
|
Survival without any stroke up to 5 year follow up
|
From procedure completion till 5 years post-procedure
|
Carotid restenosis free survival up to 1 year
Time Frame: From procedure completion till 1 year post-procedure
|
Survival without carotid restenosis requiring treatment up to 1 year follow up
|
From procedure completion till 1 year post-procedure
|
Carotid restenosis free survival up to 5 years
Time Frame: From procedure completion till 5 years post-procedure
|
Survival without carotid restenosis requiring treatment up to 5 year follow up
|
From procedure completion till 5 years post-procedure
|
Rate of carotid reintervention
Time Frame: From procedure completion till 5 years post-procedure
|
Rate of patients with clinically indicated reintervention in the index carotid artery during follow up period
|
From procedure completion till 5 years post-procedure
|
Feasibility of combined treatment
Time Frame: At the procedure completion
|
Number of patients actually treated with combined treatment (defined as the use of Micronet-covered stent and proximal cerebral protection) to the number of patients with attempted such treatment
|
At the procedure completion
|
NIHSS score change
Time Frame: At 90 days post procedure
|
Change in National Institutes of Health Stroke Scale score between the point of presentation and 90 days.
|
At 90 days post procedure
|
Freedom from stent thrombosis at 30 days
Time Frame: At 30 days post procedure
|
Freedom from clinical or ultrasound stent thrombosis detected within 30 days after procedure
|
At 30 days post procedure
|
Freedom from stent thrombosis at 90 days
Time Frame: At 90 days post procedure
|
Freedom from clinical or ultrasound stent thrombosis detected within 90 days after procedure
|
At 90 days post procedure
|
Freedom from stent thrombosis or in-stent restenosis up to 1 year
Time Frame: At 1 year after procedure
|
Freedom from clinical or ultrasound stent thrombosis or significant in-stent restenosis detected within 12 months after procedure
|
At 1 year after procedure
|
Stent thrombosis or in-stent restenosis up to 5 years
Time Frame: At 5 years after procedure
|
Clinical or ultrasound stent thrombosis or significant in-stent restenosis detected within 5 years after procedure
|
At 5 years after procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Piotr Musialek, MD, DPhil, Department of Cardiac and Vascular Diseases, John Paul II Hospital in Krakow
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAFEGUARD-STROKE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Thrombectomy and Stenting under neuroprotection
-
Boston Scientific CorporationCompletedMyocardial InfarctionItaly
-
University of PisaCompleted
-
Silk Road MedicalCompletedCarotid Artery DiseaseUnited States, Spain
-
Beijing Tiantan HospitalRecruitingBasilar Artery Occlusion | Endovascular TreatmentChina
-
Assiut UniversityUnknown
-
University of CalgaryMedtronic - MITG; Heart and Stroke Foundation of Canada; Hotchkiss Brain Institute...TerminatedIschemic StrokeCanada
-
University Hospital, GhentCompletedBiliary Strictures Post Liver TransplantationBelgium
-
Xueli CaiRecruitingStroke | Thrombectomy | Tandem OcclusionChina
-
Nanfang Hospital of Southern Medical UniversityBoston Scientific CorporationUnknownColorectal Cancer | Colonic Obstruction | Acute Malignant Colonic ObstructionChina
-
The University of Hong KongUnknownBiliary Anastomotic StenosisHong Kong